Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). (NCT06133972)
A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Who can join: Review the eligibility criteria below.
Location: Pinnacle Research Group Llc — Anniston, Alabama
Age range: 12 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (143 Sites)
Showing the first 25 of 143 sites.
- Pinnacle Research Group Llc — Anniston, Alabama
- Providence Medical Center — Burbank, California
- Advanced Medical Research — La Palma, California
- Millennium Clinical Trials — Westlake Village, California
- University of Colorado Denver — Aurora, Colorado
- Clinical Res Of W Florida — Clearwater, Florida
- GNP Research — Cooper City, Florida
- IRIS Research and Development — Plantation, Florida
- Clinical Research of West Florida Inc — Tampa, Florida
- Parris and Associates Rheumatology — Lawrenceville, Georgia
- Robert A Hozman MD SC — Skokie, Illinois
- Willow Rheumatology Wellness — Willowbrook, Illinois
- Accurate Clinical Research — Lake Charles, Louisiana
- University Of Maryland — Baltimore, Maryland
- Henry Ford Health — Detroit, Michigan
- Ahmed Arif Medical Research Center — Grand Blanc, Michigan
- Paramount Med Rsrch and Consult LLC — Middleburg Heights, Ohio
- West Tennessee Research Institute — Jackson, Tennessee
- Shelby Research LLC — Memphis, Tennessee
- Novel Research LLC — Bellaire, Texas
- Accurate Clinical Research — League City, Texas
- Epic Medical Research — Red Oak, Texas
- Novartis Investigative Site — La Plata, Buenos Aires
- Novartis Investigative Site — Quilmes, Buenos Aires
- Novartis Investigative Site — San Miguel, Buenos Aires
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.